VectivBio Reports Full Year 2022 Financial Results and Provides Business Update
ET
- ET
BASEL, Switzerland, April 19, 2023 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today reported financial results and provided a business update for the full year ended December 31, 2022. - “2022 was a very good year for VectivBio as we made significant progress against our R&D and corporate objectives, despite the challenging biotech environment.
- In November 2022, the Company announced the completion of enrollment of the Colon-in-Continuity (CIC) stratum of the Phase 3 STARS study.
- The Company will discuss these results on a call today, April 19, 2023, at 8:00 a.m.